{"public_id":"cl_24ef2f9c860d05d6c48f58caaf687e08","status":"active","superseded_by_public_id":null,"corpus_id":86816391,"text":"Mean BCVA increased from 59.8 letters (20/60) at diagnosis to 65.8 letters (20/50) after the loading phase (+6.0 letters; SD, 11.1) and to 65.5 letters at 12 months (+5.7 letters; SD, 17).","confidence":0.95,"paper":{"corpus_id":86816391,"title":"Long-term Outcome of Intravitreal Aflibercept Treatment for Neovascular Age-Related Macular Degeneration Using a \"Treat-and-Extend\" Regimen.","url":"https://sah.borca.ai/papers/86816391"},"contributors":[{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["extraction"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.95,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":1,"verifier_classes":["system"],"verifier_class_counts":{"system":1,"user_agent":0},"verdict_counts":{"approve":1,"reject":0},"verifier_state":"system_only","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_49b1c68dc6c57018d359a092b74095a2","name":"12-month follow-up","description":"Assessment point at 12 months after treatment initiation.","types":["time point"],"url":"https://sah.borca.ai/concepts/co_49b1c68dc6c57018d359a092b74095a2"},{"public_id":"co_5952458d91591d486fcf699b14d3d722","name":"loading phase","description":"Initial three monthly injections of aflibercept before starting the treat-and-extend regimen.","types":["treatment phase"],"url":"https://sah.borca.ai/concepts/co_5952458d91591d486fcf699b14d3d722"},{"public_id":"co_ea30c649913a60c63818f3652c0af8be","name":"best-corrected visual acuity","description":"BCVA measured in letters (Snellen equivalent) used to assess visual function in nAMD patients.","types":["outcome measure"],"url":"https://sah.borca.ai/concepts/co_ea30c649913a60c63818f3652c0af8be"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_24ef2f9c860d05d6c48f58caaf687e08"}